Catalent Announces Commercial Supply Agreement with Aurinia Pharmaceuticals for Newly-Approved LUPKYNIST Softgels
Catalent, the leading global provider of advanced delivery technologies,
development, and manufacturing solutions for drugs, biologics, cell and
gene therapies, and consumer health products, today announced that it
recently signed a multi-year commercial supply agreement with Aurinia
Pharmaceuticals.
More info >> |